Supernus Pharmaceuticals Inc (SUPN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Supernus Pharmaceuticals Inc stock (SUPN) is currently trading at $49.38. Supernus Pharmaceuticals Inc PS ratio (Price-to-Sales) is 3.83. Analyst consensus price target for SUPN is $63.17. WallStSmart rates SUPN as Underperform.
- SUPN PE ratio analysis and historical PE chart
- SUPN PS ratio (Price-to-Sales) history and trend
- SUPN intrinsic value — DCF, Graham Number, EPV models
- SUPN stock price prediction 2025 2026 2027 2028 2029 2030
- SUPN fair value vs current price
- SUPN insider transactions and insider buying
- Is SUPN undervalued or overvalued?
- Supernus Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- SUPN Piotroski F-Score and Altman Z-Score
- SUPN analyst price target and Smart Rating
Supernus Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Supernus Pharmaceuticals Inc (SUPN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, revenue growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Supernus Pharmaceuticals Inc (SUPN) Key Strengths (4)
103.34% of shares held by major funds and institutions
Good growth relative to its price
Strong revenue growth at 21.50% annually
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Supernus Pharmaceuticals Inc (SUPN) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Revenue is fairly priced at 3.83x sales
Fairly priced relative to book value
Solid earnings growth at 11.10%
Supernus Pharmaceuticals Inc (SUPN) Detailed Analysis Report
Overall Assessment
This company scores 50/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.3/10) while 6 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., PEG Ratio, Revenue Growth. Valuation metrics including PEG Ratio (1.47) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 21.50%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (3.83), Price/Book (2.59) suggest expensive pricing. Growth concerns include EPS Growth at 11.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -3.68%, Operating Margin at -28.90%, Profit Margin at -5.36%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -3.68% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 21.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., PEG Ratio) and negatives (Return on Equity, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SUPN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SUPN's Price-to-Sales ratio of 3.83x trades at a deep discount to its historical average of 57.77x (42th percentile). The current valuation is 100% below its historical high of 923.99x set in Jul 2012, and Infinity% above its historical low of 0x in Jan 2026. Over the past 12 months, the PS ratio has expanded from ~2.8x, reflecting growing market expectations outpacing revenue growth.
Compare SUPN with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Supernus Pharmaceuticals Inc (SUPN) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Supernus Pharmaceuticals Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 719M with 22% growth year-over-year. The company is currently unprofitable, posting a -5.4% profit margin.
Key Findings
Generating 19M in free cash flow and 20M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -5.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Supernus Pharmaceuticals Inc maintain 22%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Supernus Pharmaceuticals Inc.
Bottom Line
Supernus Pharmaceuticals Inc offers an attractive blend of growth (22% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Supernus Pharmaceuticals Inc(SUPN)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.